RenovoRx, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by RenovoRx, Inc. on February 9, 2024, covering events occurring on February 5, 2024, and February 8, 2024. The filing addresses significant changes in the Company's executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a new Principal Accounting Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CFO: James Ahlers resigned as Chief Financial Officer effective February 5, 2024. The resignation was for personal reasons and not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment of Principal Accounting Officer: On February 8, 2024, the Board appointed Ronald B. Kocak, CPA, CGMA, formerly the Vice President and Controller, to the position of Vice President, Controller, and Principal Accounting Officer. Mr. Kocak will serve as the Company's principal accounting and financial officer.
Compensation and Outlook
Mr. Kocak's appointment includes the following compensation terms effective February 9, 2024:
- Base Salary: $235,000 annually.
- Annual Incentive Bonus: Target up to 35% of base salary, subject to Board discretion.
- Equity Grant: An option to purchase 15,000 shares of common stock at an exercise price of $1.56 per share.
- Vesting Schedule: The option vests monthly over four years (1/48th per month) subject to continued service. The grant includes a double-trigger vesting provision upon a Change in Control.
The filing contains no specific financial guidance, risk factors, or contingencies beyond the standard disclosure of executive compensation and employment terms.
Investor Verification Checklist
- Verify the effective date of James Ahlers' resignation and confirm no undisclosed disputes exist.
- Review the attached Exhibit 10.1 (Amended and Restated Offer Letter) for full details on Mr. Kocak's employment terms.
- Confirm the impact of the CFO departure on the Company's financial reporting timeline and internal controls.
- Assess the dilution impact of the 15,000 share option grant on existing shareholders.